DOI:
10.1055/s-00043364
Pharmaceutical Fronts
LinksClose Window
References
Andreev J, Thambi N, Perez Bay AE. et al.
Bispecific antibodies and antibody-drug conjugates (ADCs) bridging HER2 and prolactin receptor improve efficacy of HER2 ADCs.
Mol Cancer Ther 2017;
16 (04) 681-693
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.